TP53 and astrocytoma (excluding glioblastoma): Further, the TCGA LGG astrocytoma dataset showed significantly improved PFS for TP53 mutant cases (TP53 WT 18 months vs. TP53 MT 42 months, p < 0.001) (Figure 2C,D).